// App-Quantinova.ai

134 : Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951

Researchers

Presenter

  • Stefan Suciu

Principal Investigators

  • Pierre Rohrlich

  • Martine Munzer

  • Maryline Poiree

  • Patrick Boutard

  • Frederic Millot

  • Dominique Plantaz

  • Philip Maes

  • Claire Hoyoux

  • Helene Cave

  • Yves Bertrand

  • Alina Ferster

  • Yves Benoit

  • Francoise Mazingue

  • Genevieve Plat

  • Karima Yakouben

  • Anne Uyttebroeck

  • Patrick Lutz

  • Vitor Costa

  • Nicolas Sirvent

Medical Centers

  • Pediatric Hematology Unit, CHU Jean Minjoz Hospital, Besancon, France

  • Department of Hematology, Grenoble University Hospital, Grenoble, France

  • Pediatric Oncology, University Hospital, Lille, France

  • Department of Pediatric Hematology-Oncology, CHU, Caen, France,

  • Department of Pediatric Hematology-Oncology, CHU, Caen, France,

  • Department of Genetics, Robert Debre Hospital, APHP, Paris, France

  • Department of Paediatric Surgery, CHR de la Citadelle, Liege, Belgium

  • Department of Radiology, University Hospital Gasthuisberg, Leuven, Belgium

  • Institute of Pediatric Hematology and Oncology, Lyon Hospital, Lyon, France

  • Dept. of Pediatric Hematology, Robert Debre hospital, APHP, Paris, France

  • Department of Radiation Oncology, Ghent University Hospital, Gent, Belgium

  • Department of Pediatric Hematology-Oncology, University Hospital Hautepierre, Strasbourg, France

  • Department of Pediatric Hematology-Oncology, CHU, Caen, France,

  • Department of Pediatric Hematology-Oncology, CHU, Caen, France,

  • Department of Radiation Oncology, Ghent University Hospital, Gent, Belgium

  • Department of Pediatric Hematology-Oncology, American Memorial Hospital, Reims, France

  • Department of Medical Genetics, University of Antwerp, Antwerp, Belgium

  • EORTC Headquarters, Brussels, Belgium

  • Department of Pediatric Onco-Hematology, CHU-Hopital Purpan, Toulouse, France

  • Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal

Locations

  • France

  • Portugal

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Prednisolone

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved